Paper of the Month: May 2023
Prioritising respiratory syncytial virus prevention inlow-income and middle-income countries
Xavier Carbonell-Estrany et al.
RSV disease burden in children below 5 in 72 GAVI eligible countries.
Image from: Li, X. et al. BMC Med 18, 82 (2020). https://doi.org/10.1186/s12916-020-01537-6
Over the past few years, the advent of several preventive interventions finally provides opportunities to address the burden of respiratory syncytial virus disease. However, in the past, new vaccines to prevent important respiratory illnesses were author…
RSVVW’24 Conference Mumbai
We are delighted to announce that on 14-16 February 2024, the ReSViNET Foundation will host its 8th conference RSVVW’24 – A Global Conference on Novel RSV Preventive and Therapeutic Interventions. After a successful conference in 2022, held in Lisbon, Portugal, we are looking forward to welcoming you at our next in-person conference in Mumbai, India.
Paper of the Month: April 2023
Nirsevimab is an extended half-life monoclonal antibody to the respiratory syncytial virus (RSV) fusion protein that has been developed to protect infants for an entire RSV season. Previous studies have shown that the nirsevimab binding site is highly conserved. However, investigations of the geotemporal evolution of potential escape variants in recent (ie, 2015–2021)…
This is how you can help: participate in our survey and spread the word!
Help us understand parents’ awareness of RSV, and their needs when vaccinating their child. It will only take 2-3 minutes of your time.
We are proud to announce we have developed the first-ever global RSV surveillance dashboard and it is now live!
ReSViNET Foundation, in collaboration with AstraZeneca, is supporting healthcare decisions by providing transparency and accessibility to shared global RSV surveillance data. The dashboard will help simplify tracking changes in RSV seasonality globally. This will include at least 20 countries that are representative of different geographic regions from both hemispheres.